RO7234292 (RG6042)

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Huntingtons Disease

Conditions

Huntingtons Disease

Trial Timeline

Sep 2, 2019 → Jan 18, 2022

NCT ID

NCT04000594

About RO7234292 (RG6042)

RO7234292 (RG6042) is a phase 1 stage product being developed by Roche for Huntingtons Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04000594. Target conditions include Huntingtons Disease.

What happened to similar drugs?

0 of 1 similar drugs in Huntingtons Disease were approved

Approved (0) Terminated (0) Active (1)

🔄RO7234292 + PlaceboRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04000594	Phase 1	Completed	Sep 2, 2019	Jan 18, 2022	Huntingtons Disease
NCT03842969	Phase 3	Completed	Apr 23, 2019	Mar 30, 2022	Huntington Disease
NCT03342053	Phase 2	Completed	Jan 2, 2018	Oct 8, 2019	Huntington's Disease

Competing Products

1 competing product in Huntingtons Disease

See all competitors

Product	Company	Stage	Hype Score
RO7234292 + Placebo	Roche	Phase 3	40